Intensity Therapeutics Reports Promising Phase 1/2 Results for INT230-6 in Advanced Solid Tumors

Reuters

Oct 30, 2025

Intensity <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Promising Phase 1/2 Results for INT230-6 in Advanced Solid Tumors

Intensity Therapeutics, Inc. announced the publication of clinical results from its phase 1/2 IT-01 clinical study investigating INT230-6 for the treatment of metastatic or refractory cancers. The results, published in eBioMedicine, a Lancet Discovery Science journal, include data on disease control rate, overall survival, immune activation, and safety. The study evaluated INT230-6 administered intratumorally in adult patients with advanced solid tumors, reporting a disease control rate of 75% and a median overall survival of 11.9 months among heavily pretreated patients with over 20 types of cancer. These results were published on October 29, 2025, and will be discussed in a webinar on October 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE10992) on October 30, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2579487301"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579487301\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579487301?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579487301","market":"fut","top_or_hot":-1,"title":"Intensity Therapeutics Reports Promising Phase 1/2 Results for INT230-6 in Advanced Solid Tumors","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Intensity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Promising Phase 1/2 Results for INT230-6 in Advanced Solid Tumors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/INTS\">Intensity Therapeutics, Inc.</a> announced the publication of clinical results from its phase 1/2 IT-01 clinical study investigating INT230-6 for the treatment of metastatic or refractory cancers. The results, published in eBioMedicine, a Lancet Discovery Science journal, include data on disease control rate, overall survival, immune activation, and safety. The study evaluated INT230-6 administered intratumorally in adult patients with advanced solid tumors, reporting a disease control rate of 75% and a median overall survival of 11.9 months among heavily pretreated patients with over 20 types of cancer. These results were published on October 29, 2025, and will be discussed in a webinar on October 31, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE10992) on October 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intensity Therapeutics Reports Promising Phase 1/2 Results for INT230-6 in Advanced Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntensity Therapeutics Reports Promising Phase 1/2 Results for INT230-6 in Advanced Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-30 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Intensity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Promising Phase 1/2 Results for INT230-6 in Advanced Solid Tumors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/INTS\">Intensity Therapeutics, Inc.</a> announced the publication of clinical results from its phase 1/2 IT-01 clinical study investigating INT230-6 for the treatment of metastatic or refractory cancers. The results, published in eBioMedicine, a Lancet Discovery Science journal, include data on disease control rate, overall survival, immune activation, and safety. The study evaluated INT230-6 administered intratumorally in adult patients with advanced solid tumors, reporting a disease control rate of 75% and a median overall survival of 11.9 months among heavily pretreated patients with over 20 types of cancer. These results were published on October 29, 2025, and will be discussed in a webinar on October 31, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE10992) on October 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INTS","symbol_name":"Intensity Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL4KpZdF:1","article_id":"2579487301","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579487301","pubTimestamp":1761823842,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Intensity Therapeutics, Inc. announced the publication of clinical results from its phase 1/2 IT-01 clinical study investigating INT230-6 for the treatment of metastatic or refractory cancers. The results, published in eBioMedicine, a Lancet Discovery Science journal, include data on disease control rate, overall survival, immune activation, and safety. The study evaluated INT230-6 administered intratumorally in adult patients with advanced solid tumors, reporting a disease control rate of 75% and a median overall survival of 11.9 months among heavily pretreated patients with over 20 types of cancer. These results were published on October 29, 2025, and will be discussed in a webinar on October 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, o","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INTS":"Intensity Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Intensity Therapeutics报告INT230-6在晚期实体瘤中的有希望的1/2期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INTS":0.9},"content_text":"Intensity Therapeutics Reports Promising Phase 1/2 Results for INT230-6 in Advanced Solid Tumors\n    \n\nIntensity Therapeutics, Inc. announced the publication of clinical results from its phase 1/2 IT-01 clinical study investigating INT230-6 for the treatment of metastatic or refractory cancers. The results, published in eBioMedicine, a Lancet Discovery Science journal, include data on disease control rate, overall survival, immune activation, and safety. The study evaluated INT230-6 administered intratumorally in adult patients with advanced solid tumors, reporting a disease control rate of 75% and a median overall survival of 11.9 months among heavily pretreated patients with over 20 types of cancer. These results were published on October 29, 2025, and will be discussed in a webinar on October 31, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE10992) on October 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}